{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:58:20Z","timestamp":1777931900293,"version":"3.51.4"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00223-020-00788-y","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T04:17:11Z","timestamp":1609561031000},"page":"486-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Old and New Drugs for the Management of Bone Disorders in CKD"],"prefix":"10.1007","volume":"108","author":[{"given":"Hirotaka","family":"Komaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-2339","authenticated-orcid":false,"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"788_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370\u20131378","journal-title":"Kidney Int"},{"key":"788_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","volume":"44","author":"T Shigematsu","year":"2004","unstructured":"Shigematsu T, Kazama JJ, Yamashita T et al (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250\u2013256","journal-title":"Am J Kidney Dis"},{"key":"788_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E et al (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205\u20132215","journal-title":"J Am Soc Nephrol"},{"key":"788_CR4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1172\/JCI116720","volume":"92","author":"N Fukuda","year":"1993","unstructured":"Fukuda N, Tanaka H, Tominaga Y et al (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436\u20131443","journal-title":"J Clin Invest"},{"key":"788_CR5","first-page":"1598","volume":"81","author":"O Kifor","year":"1996","unstructured":"Kifor O, Moore FD Jr, Wang P et al (1996) Reduced immunostaining for the extracellular Ca2\u00fe-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81:1598\u20131606","journal-title":"J Clin Endocrinol Metab"},{"key":"788_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/ki.2009.414","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Goto S, Fujii H et al (2010) Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77:232\u2013238","journal-title":"Kidney Int"},{"key":"788_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrneph.2012.116","volume":"8","author":"H Komaba","year":"2012","unstructured":"Komaba H, Fukagawa M (2012) The role of FGF23 in CKD\u2014with or without Klotho. Nat Rev Nephrol 8:484\u2013490","journal-title":"Nat Rev Nephrol"},{"key":"788_CR8","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"788_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/ki.1993.64","volume":"43","author":"DJ Sherrard","year":"1993","unstructured":"Sherrard DJ, Hercz G, Pei Y et al (1993) The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int 43:436\u2013442","journal-title":"Kidney Int"},{"key":"788_CR10","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113:S1\u2013S130","journal-title":"Kidney Int Suppl"},{"key":"788_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358\u20131366","journal-title":"Kidney Int"},{"key":"788_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1053\/ajkd.2000.19812","volume":"36","author":"M Coco","year":"2000","unstructured":"Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115\u20131121","journal-title":"Am J Kidney Dis"},{"key":"788_CR13","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516\u20131525","journal-title":"N Engl J Med"},{"key":"788_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266\u2013281","journal-title":"N Engl J Med"},{"key":"788_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/ki.2012.176","volume":"82","author":"M Wolf","year":"2012","unstructured":"Wolf M (2012) Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82:737\u2013747","journal-title":"Kidney Int"},{"key":"788_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1525-139X.2005.18407.x","volume":"18","author":"GO Wolisi","year":"2005","unstructured":"Wolisi GO, Moe SM (2005) The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 18:307\u2013314","journal-title":"Semin Dial"},{"key":"788_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Update Work Group (2017) KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359","journal-title":"Kidney Int Suppl"},{"key":"788_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674\u2013684","journal-title":"JAMA"},{"key":"788_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY Wang","year":"2014","unstructured":"Wang AY, Fang F, Chan J et al (2014) Effect of paricalcitol on left ventricular mass and function in CKD: the OPERA trial. J Am Soc Nephrol 25:175\u2013186","journal-title":"J Am Soc Nephrol"},{"key":"788_CR20","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1152\/ajpendo.00224.2004","volume":"288","author":"W Xiang","year":"2005","unstructured":"Xiang W, Kong J, Chen S et al (2005) Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288:E125\u2013E132","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"788_CR21","doi-asserted-by":"publisher","first-page":"16810","DOI":"10.1073\/pnas.0611202104","volume":"104","author":"N Bodyak","year":"2007","unstructured":"Bodyak N, Ayus JC, Achinger S et al (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 104:16810\u201316815","journal-title":"Proc Natl Acad Sci USA"},{"key":"788_CR22","first-page":"185","volume":"26","author":"LR Baker","year":"1986","unstructured":"Baker LR, Muir JW, Sharman VL et al (1986) Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 26:185\u2013191","journal-title":"Clin Nephrol"},{"key":"788_CR23","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","volume":"15","author":"GM London","year":"2004","unstructured":"London GM, Marty C, Marchais SJ et al (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943\u20131951","journal-title":"J Am Soc Nephrol"},{"key":"788_CR24","first-page":"126","volume":"32","author":"VM Brandenburg","year":"2017","unstructured":"Brandenburg VM, Kramann R, Rothe H et al (2017) Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant 32:126\u2013132","journal-title":"Nephrol Dial Transplant"},{"key":"788_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F et al (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17:247\u2013288","journal-title":"Ther Apher Dial"},{"key":"788_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1523-1755.2004.00432.x","volume":"65","author":"A Torres","year":"2004","unstructured":"Torres A, Garcia S, Gomez A et al (2004) Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 65:705\u2013712","journal-title":"Kidney Int"},{"key":"788_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ki.2008.501","volume":"75","author":"P Ravani","year":"2009","unstructured":"Ravani P, Malberti F, Tripepi G et al (2009) Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:88\u201395","journal-title":"Kidney Int"},{"key":"788_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00467-010-1526-x","volume":"26","author":"PH Biggar","year":"2011","unstructured":"Biggar PH, Liangos O, Fey H et al (2011) Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug? Pediatr Nephrol 26:7\u201318","journal-title":"Pediatr Nephrol"},{"key":"788_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1681\/ASN.2009040451","volume":"21","author":"JR Stubbs","year":"2010","unstructured":"Stubbs JR, Idiculla A, Slusser J et al (2010) Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 21:353\u2013361","journal-title":"J Am Soc Nephrol"},{"key":"788_CR30","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/ndt\/gfw080","volume":"31","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Georgianos PI (2016) Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 31:706\u2013713","journal-title":"Nephrol Dial Transplant"},{"key":"788_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/jc.2010-2704","volume":"96","author":"AC Ross","year":"2011","unstructured":"Ross AC, Manson JE, Abrams SA et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53\u201358","journal-title":"J Clin Endocrinol Metab"},{"key":"788_CR32","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911\u20131930","journal-title":"J Clin Endocrinol Metab"},{"key":"788_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2215\/CJN.07131009","volume":"5","author":"SM Moe","year":"2010","unstructured":"Moe SM, Saifullah A, LaClair RE et al (2010) A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 5:299\u2013306","journal-title":"Clin J Am Soc Nephrol"},{"key":"788_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/17446651.2017.1347501","volume":"12","author":"SM Sprague","year":"2017","unstructured":"Sprague SM, Strugnell SA, Bishop CW (2017) Extended-release calcifediol for secondary hyperparathyroidism in stage 3\u20134 chronic kidney disease. Expert Rev Endocrinol Metab 12:289\u2013301","journal-title":"Expert Rev Endocrinol Metab"},{"key":"788_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000499187","volume":"49","author":"SA Strugnell","year":"2019","unstructured":"Strugnell SA, Sprague SM, Ashfaq A et al (2019) Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease. Am J Nephrol 49:284\u2013293","journal-title":"Am J Nephrol"},{"key":"788_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/366575a0","volume":"366","author":"EM Brown","year":"1993","unstructured":"Brown EM, Gamba G, Riccardi D et al (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575\u2013580","journal-title":"Nature"},{"key":"788_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1006\/bbrc.1995.2318","volume":"214","author":"K Aida","year":"1995","unstructured":"Aida K, Koishi S, Tawata M et al (1995) Molecular cloning of a putative Ca(2+)-sensing receptor cDNA from human kidney. Biochem Biophys Res Commun 214:524\u2013529","journal-title":"Biochem Biophys Res Commun"},{"key":"788_CR38","doi-asserted-by":"publisher","first-page":"C221","DOI":"10.1152\/ajpcell.00139.2014","volume":"307","author":"I Alfadda","year":"2014","unstructured":"Alfadda I, Saleh AMA, Houillier P et al (2014) Calcium-sensing receptor 20 years later. Am J Physiol Cell Physiol 307:C221\u2013C231","journal-title":"Am J Physiol Cell Physiol"},{"key":"788_CR39","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/oxfordjournals.ndt.a027665","volume":"11","author":"PK Nielsen","year":"1996","unstructured":"Nielsen PK, Feldt-Rasmussen U, Olgaard K (1996) A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant 11:1762\u20131768","journal-title":"Nephrol Dial Transplant"},{"key":"788_CR40","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/jbmr.5650110714","volume":"11","author":"Y Almaden","year":"1996","unstructured":"Almaden Y, Canalejo A, Hernandez A et al (1996) Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 11:970\u2013976","journal-title":"J Bone Miner Res"},{"key":"788_CR41","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","volume":"10","author":"PP Centeno","year":"2019","unstructured":"Centeno PP, Herberger A, Mun HC et al (2019) Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nature Commun 10:4693","journal-title":"Nature Commun"},{"key":"788_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","volume":"98","author":"EF Nemeth","year":"2016","unstructured":"Nemeth EF, Goodman WG (2016) Calcimimetic and calcilytic drugs: feats, flops, and futures. Calcif Tissue Int 98:341\u2013358","journal-title":"Calcif Tissue Int"},{"key":"788_CR43","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1681\/ASN.2007121320","volume":"19","author":"C Valle","year":"2008","unstructured":"Valle C, Rodriguez M, Santamar\u00eda R et al (2008) Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol 19:2430\u20132436","journal-title":"J Am Soc Nephrol"},{"key":"788_CR44","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","volume":"20","author":"SM Moe","year":"2005","unstructured":"Moe SM, Cunningham J, Bommer J et al (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20:2186\u20132193","journal-title":"Nephrol Dial Transplant"},{"key":"788_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J et al (2013) Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346:229\u2013240","journal-title":"J Pharmacol Exp Ther"},{"key":"788_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cunningham J et al (2017) Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 317:146\u2013155","journal-title":"JAMA"},{"key":"788_CR47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S et al (2017) Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 317:156\u2013164","journal-title":"JAMA"},{"key":"788_CR48","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1172\/JCI9038","volume":"105","author":"M Gowen","year":"2000","unstructured":"Gowen M, Stroup GB, Dodds RA et al (2000) Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595\u20131604","journal-title":"J Clin Invest"},{"key":"788_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","volume":"22","author":"BC Silve","year":"2015","unstructured":"Silve BC, Bilezikian JP (2015) Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol 22:41\u201350","journal-title":"Curr Opin Pharmacol"},{"key":"788_CR50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2174\/1874467211205020182","volume":"5","author":"D Riccardi","year":"2012","unstructured":"Riccardi D (2012) Antagonizing the calcium-sensing receptor: towards new bone anabolics? Curr Mol Pharmacol 5:182\u2013188","journal-title":"Curr Mol Pharmacol"},{"key":"788_CR51","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1210\/jc.2010-2855","volume":"96","author":"LA Fitzpatrick","year":"2011","unstructured":"Fitzpatrick LA, Dabrowski CE, Cicconetti G et al (2011) The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 96:2441\u20132449","journal-title":"J Clin Endocrinol Metab"},{"key":"788_CR52","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/jcb.25447","volume":"117","author":"SA Al-Dujaili","year":"2016","unstructured":"Al-Dujaili SA, Koh AJ, Dang M et al (2016) Calcium sensing receptor function supports osteoblast survival and acts as a co-factor in PTH anabolic actions in bone. J Cell Biochem 117:1556\u20131567","journal-title":"J Cell Biochem"},{"key":"788_CR53","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.kint.2018.12.015","volume":"95","author":"JM D\u00edaz-Tocados","year":"2019","unstructured":"D\u00edaz-Tocados JM, Rodr\u00edguez-Ortiz ME, Almad\u00e9n Y et al (2019) Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int 95:1064\u20131078","journal-title":"Kidney Int"},{"key":"788_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5414\/CNP69269","volume":"69","author":"HH Malluche","year":"2008","unstructured":"Malluche HH, Monier-Faugere MC, Wang G et al (2008) An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69:269\u2013278","journal-title":"Clin Nephrol"},{"key":"788_CR55","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/ki.2014.349","volume":"87","author":"GJ Behets","year":"2015","unstructured":"Behets GJ, Spasovski G, Sterling LR et al (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846\u2013856","journal-title":"Kidney Int"},{"key":"788_CR56","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s10157-017-1442-5","volume":"22","author":"T Shigematsu","year":"2018","unstructured":"Shigematsu T, Fukagawa M, Yokoyama K et al (2018) Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 22:426\u2013436","journal-title":"Clin Exp Nephrol"},{"key":"788_CR57","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J, Danese M, Olson K et al (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793\u20131800","journal-title":"Kidney Int"},{"key":"788_CR58","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1681\/ASN.2014040414","volume":"26","author":"SM Moe","year":"2015","unstructured":"Moe SM, Abdalla S, Chertow GM et al (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol 26:1466\u20131475","journal-title":"J Am Soc Nephrol"},{"key":"788_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bone.2017.08.026","volume":"105","author":"X Li","year":"2017","unstructured":"Li X, Yu L, Asuncion F et al (2017) Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. Bone 105:163\u2013172","journal-title":"Bone"},{"key":"788_CR60","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","volume":"94","author":"M Fukagawa","year":"2018","unstructured":"Fukagawa M, Shimazaki R, Akizawa T (2018) Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 94:818\u2013825","journal-title":"Kidney Int"},{"key":"788_CR61","doi-asserted-by":"publisher","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","volume":"13","author":"T Kawata","year":"2018","unstructured":"Kawata T, Tokunaga S, Murai M et al (2018) A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS ONE 13:e0195316","journal-title":"PLoS ONE"},{"key":"788_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ndt\/gfv291","volume":"31","author":"JB Wetmore","year":"2016","unstructured":"Wetmore JB, Liu J, Do TP et al (2016) Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy. Nephrol Dial Transplant 31:103\u2013111","journal-title":"Nephrol Dial Transplant"},{"key":"788_CR63","doi-asserted-by":"publisher","first-page":"E652","DOI":"10.1210\/jc.2013-4050","volume":"99","author":"H Takahashi","year":"2014","unstructured":"Takahashi H, Komaba H, Takahashi Y et al (2014) Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab 99:E652\u2013E658","journal-title":"J Clin Endocrinol Metab"},{"key":"788_CR64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0272-6386(03)00909-0","volume":"42","author":"A Yajima","year":"2003","unstructured":"Yajima A, Ogawa Y, Takahashi HE et al (2003) Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 42:729\u2013738","journal-title":"Am J Kidney Dis"},{"key":"788_CR65","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/ki.2008.242","volume":"74","author":"A Yajima","year":"2008","unstructured":"Yajima A, Inaba M, Tominaga Y et al (2008) Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 74:775\u2013781","journal-title":"Kidney Int"},{"key":"788_CR66","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1210\/jcem.83.11.5249","volume":"83","author":"M Abdelhadi","year":"1998","unstructured":"Abdelhadi M, Nordenstr\u00f6m J (1998) Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 83:3845\u20133851","journal-title":"J Clin Endocrinol Metab"},{"key":"788_CR67","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1001\/archsurg.136.9.1064","volume":"136","author":"FF Chou","year":"2001","unstructured":"Chou FF, Chen JB, Lee CH et al (2001) Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Arch Surg 136:1064\u20131068","journal-title":"Arch Surg"},{"key":"788_CR68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori S, Mori Y, Akita W et al (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2013a single-center cohort study. Nephrol Dial Transplant 27:345\u2013351","journal-title":"Nephrol Dial Transplant"},{"key":"788_CR69","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.kint.2020.02.035","volume":"98","author":"Y Nakagawa","year":"2020","unstructured":"Nakagawa Y, Komaba H, Hamano N et al (2020) Metacarpal bone mineral density by radiographic absorptiometry predicts fracture risk in patients undergoing maintenance hemodialysis. Kidney Int 98:970\u2013978","journal-title":"Kidney Int"},{"key":"788_CR70","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ki.2013.279","volume":"85","author":"F Tentori","year":"2014","unstructured":"Tentori F, McCullough K, Kilpatrick RD et al (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166\u2013173","journal-title":"Kidney Int"},{"key":"788_CR71","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1681\/ASN.2007010022","volume":"18","author":"KD Rudser","year":"2007","unstructured":"Rudser KD, de Boer IH, Dooley A et al (2007) Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18:2401\u20132407","journal-title":"J Am Soc Nephrol"},{"key":"788_CR72","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/MNH.0000000000000326","volume":"26","author":"H Komaba","year":"2017","unstructured":"Komaba H, Nakamura M, Fukagawa M (2017) Resurgence of parathyroidectomy: evidence and outcomes. Curr Opin Nephrol Hypertens 26:243\u2013249","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"788_CR73","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"J Floege","year":"2011","unstructured":"Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26:1948\u20131955","journal-title":"Nephrol Dial Transplant"},{"key":"788_CR74","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/ki.2015.72","volume":"88","author":"H Komaba","year":"2015","unstructured":"Komaba H, Taniguchi M, Wada A et al (2015) Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88:350\u2013359","journal-title":"Kidney Int"},{"key":"788_CR75","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","volume":"89","author":"TB Dr\u00fceke","year":"2016","unstructured":"Dr\u00fceke TB, Massy ZA (2016) Changing bone patterns with progression of chronic kidney disease. Kidney Int 89:289\u2013302","journal-title":"Kidney Int"},{"key":"788_CR76","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1056\/NEJM197601222940402","volume":"294","author":"AC Alfrey","year":"1976","unstructured":"Alfrey AC, LeGendre GR, Kaehny WD (1976) The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294:184\u2013188","journal-title":"N Engl J Med"},{"key":"788_CR77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(83)90014-4","volume":"2","author":"MR Wills","year":"1983","unstructured":"Wills MR, Savory J (1983) Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Lancet 2:29\u201334","journal-title":"Lancet"},{"key":"788_CR78","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1681\/ASN.2006101089","volume":"19","author":"A Ferreira","year":"2008","unstructured":"Ferreira A, Fraz\u00e3o JM, Monier-Faugere MC et al (2008) Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19:405\u2013412","journal-title":"J Am Soc Nephrol"},{"key":"788_CR79","first-page":"130","volume":"20","author":"M Rudnicki","year":"1994","unstructured":"Rudnicki M, Hyldstrup L, Petersen LJ et al (1994) Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double-blind placebo-controlled study. Miner Electrolyte Metab 20:130\u2013134","journal-title":"Miner Electrolyte Metab"},{"key":"788_CR80","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS et al (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23:1407\u20131415","journal-title":"J Am Soc Nephrol"},{"key":"788_CR81","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","volume":"51","author":"W Qunibi","year":"2008","unstructured":"Qunibi W, Moustafa M, Muenz LR et al (2008) A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51:952\u2013965","journal-title":"Am J Kidney Dis"},{"key":"788_CR82","doi-asserted-by":"publisher","first-page":"c273","DOI":"10.1159\/000170783","volume":"110","author":"DV Barreto","year":"2008","unstructured":"Barreto DV, Barreto Fde C, de Carvalho AB et al (2008) Phosphate binder impact on bone remodeling and coronary calcification: results from the BRiC study. Nephron Clin Pract 110:c273\u2013c283","journal-title":"Nephron Clin Pract"},{"key":"788_CR83","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","volume":"85","author":"PC D'Haese","year":"2003","unstructured":"D\u2019Haese PC, Spasovski GB, Sikole A et al (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 85:S73\u2013S78","journal-title":"Kidney Int Suppl"},{"key":"788_CR84","first-page":"284","volume":"70","author":"HH Malluche","year":"2008","unstructured":"Malluche HH, Siami GA, Swanepoel C et al (2008) Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70:284\u2013295","journal-title":"Clin Nephrol"},{"key":"788_CR85","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","volume":"21","author":"GB Spasovski","year":"2006","unstructured":"Spasovski GB, Sikole A, Gelev S et al (2006) Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 21:2217\u20132224","journal-title":"Nephrol Dial Transplant"},{"key":"788_CR86","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1744-9987.2010.00898.x","volume":"15","author":"T Shigematsu","year":"2011","unstructured":"Shigematsu T, Tokumoto A, Nakaoka A et al (2011) Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial 15:76\u2013184","journal-title":"Ther Apher Dial"},{"key":"788_CR87","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000492603","volume":"140","author":"A Hutchison","year":"2018","unstructured":"Hutchison A, Whelton A, Thadhani R et al (2018) Long-term mortality and bone safety in patients with end-stage renal disease receiving lanthanum carbonate. Nephron 140:265\u2013274","journal-title":"Nephron"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-020-00788-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:06:39Z","timestamp":1674806799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-020-00788-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s00223-020-00788-y","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Hirotaka Komaba has received honoraria, consulting fees, and\/or grant support from Bayer Yakuhin, Chugai Pharmaceutical, Japan Tobacco, Kyowa Kirin, Novartis, and Ono Pharmaceutical. Markus Ketteler has received honoraria for consulting and lecture fees from Amgen, Bayer, Kyowa Kirin, Medice, Ono Pharmaceutical, Sanofi, and Vifor Pharma. John Cunningham has receive honoraria, consulting fees, and\/or grant support from Vifor Pharma, Amgen, Merck, and Opko Pharma. Masafumi Fukagawa has received honoraria, consulting fees, and\/or grant support from Bayer Yakuhin, Fresenius Kabi, Kissei Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, and Torii Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}